J Menopausal Med.  2015 Apr;21(1):28-35. 10.6118/jmm.2015.21.1.28.

Is Complementary and Alternative Therapy Effective for Women in the Climacteric Period?

• Kim MY
• Choi SD
• Ryu A

• KMID: 2201019
• DOI: http://doi.org/10.6118/jmm.2015.21.1.28

Abstract

Vasomotor symptoms start about 2 years prior to menopause in women who are approaching menopause, and early menopause symptoms appear including emotional disturbance and anxiety, followed by physical changes such as vaginal dryness, urinary incontinence and skin wrinkles. As time progresses, osteoporosis, cardiovascular diseases, and dementia occur consecutively. Hormone therapy is primarily considered for the relief of menopause symptoms in postmenopausal women. However, as hormone replacement has emerged as a therapy that increases the potential risk of thrombosis, cerebral infarction and breast cancer, complementary and alternative medicine has drawn much attention. This study aimed to examine the types and effects of evidence-based complementary and alternative therapies that are currently used.

Keyword

Climacteric; Complementary therapies; Postmenopause

MeSH Terms

Affective Symptoms
Anxiety
Breast Neoplasms
Cardiovascular Diseases
Climacteric*
Complementary Therapies
Dementia
Female
Humans
Infarction
Intracranial Thrombosis
Menopause
Osteoporosis
Postmenopause
Skin
Urinary Incontinence

Reference

1. National Center for Complementary and Integrative Health. Complementary, alternative, or integrative health: what's in a name? Bethesda, MD: National Institutes of Health;2008. cited by 2015 March 1. Available from: https://nccih.nih.gov/health/integrative-health.

2. Geller SE, Studee L. Botanical and dietary supplements for menopausal symptoms: what works, what does not. J Womens Health (Larchmt). 2005; 14:634–649.

3. Pitkin J. Alternative and complementary therapies for the menopause. Menopause Int. 2012; 18:20–27.

4. Zand RS, Jenkins DJ, Diamandis EP. Steroid hormone activity of flavonoids and related compounds. Breast Cancer Res Treat. 2000; 62:35–49.

5. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. 1996; 93:5925–5930.

6. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998; 139:4252–4263.

7. Lindner HR. Occurrence of anabolic agents in plants and their importance. Environ Qual Saf Suppl. 1976; 151–8.

8. Farnsworth NR, Bingel AS, Cordell GA, Crane FA, Fong HS. Potential value of plants as sources of new antifertility agents II. J Pharm Sci. 1975; 64:717–754.

9. Kelly GE, Joannou GE, Reeder AY, Nelson C, Waring MA. The variable metabolic response to dietary isoflavones in humans. Proc Soc Exp Biol Med. 1995; 208:40–43.

10. Joannou GE, Kelly GE, Reeder AY, Waring M, Nelson C. A urinary profile study of dietary phytoestrogens. The identification and mode of metabolism of new isoflavonoids. J Steroid Biochem Mol Biol. 1995; 54:167–184.

11. Kelly GE, Nelson C, Waring MA, Joannou GE, Reeder AY. Metabolites of dietary (soya) isoflavones in human urine. Clin Chim Acta. 1993; 223:9–22.

12. Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J Nutr. 1999; 129:758S–767S.

13. Jacobs A, Wegewitz U, Sommerfeld C, Grossklaus R, Lampen A. Efficacy of isoflavones in relieving vasomotor menopausal symptoms - A systematic review. Mol Nutr Food Res. 2009; 53:1084–1097.

14. Tempfer CB, Bentz EK, Leodolter S, Tscherne G, Reuss F, Cross HS, et al. Phytoestrogens in clinical practice: a review of the literature. Fertil Steril. 2007; 87:1243–1249.

15. Setchell KD, Brown NM, Zimmer-Nechemias L, Brashear WT, Wolfe BE, Kirschner AS, et al. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr. 2002; 76:447–453.

16. Messina M, Ho S, Alekel DL. Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data. Curr Opin Clin Nutr Metab Care. 2004; 7:649–658.

17. Ma DF, Qin LQ, Wang PY, Katoh R. Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials. Clin Nutr. 2008; 27:57–64.

18. Food and Drug Administration. Food labeling: health claims; soy protein and coronary heart disease. Food and Drug Administration, HHS. Final rule. Fed Regist. 1999; 64:57700–57733.

19. Rudkowska I. Functional foods for cardiovascular disease in women. Menopause Int. 2008; 14:63–69.

20. Dodin S, Lemay A, Jacques H, Légaré F, Forest JC, Mâsse B. The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J Clin Endocrinol Metab. 2005; 90:1390–1397.

21. Lewis JE, Nickell LA, Thompson LU, Szalai JP, Kiss A, Hilditch JR. A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause. Menopause. 2006; 13:631–642.

22. Simbalista RL, Sauerbronn AV, Aldrighi JM, Arêas JA. Consumption of a flaxseed-rich food is not more effective than a placebo in alleviating the climacteric symptoms of postmenopausal women. J Nutr. 2010; 140:293–297.

23. Lucas EA, Wild RD, Hammond LJ, Khalil DA, Juma S, Daggy BP, et al. Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. J Clin Endocrinol Metab. 2002; 87:1527–1532.

24. Pan A, Yu D, Demark-Wahnefried W, Franco OH, Lin X. Meta-analysis of the effects of flaxseed interventions on blood lipids. Am J Clin Nutr. 2009; 90:288–297.

25. Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa) for menopausal symptoms: a systematic review of its efficacy. Pharmacol Res. 2008; 58:8–14.

26. Nadaoka I, Yasue M, Sami M, Kitagawa Y. Oral administration of Cimicifuga racemosa extract affects immobilization stress-induced changes in murine cerebral monoamine metabolism. Biomed Res. 2012; 33:133–137.

27. Borrelli F, Ernst E. Alternative and complementary therapies for the menopause. Maturitas. 2010; 66:333–343.

28. Al-Akoum M, Maunsell E, Verreault R, Provencher L, Otis H, Dodin S. Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial. Menopause. 2009; 16:307–314.

29. Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril. 1997; 68:981–986.

30. Kupfersztain C, Rotem C, Fagot R, Kaplan B. The immediate effect of natural plant extract, Angelica sinensis and Matricaria chamomilla (Climex) for the treatment of hot flushes during menopause. A preliminary report. Clin Exp Obstet Gynecol. 2003; 30:203–206.

31. Chang A, Kwak BY, Yi K, Kim JS. The effect of herbal extract (EstroG-100) on pre-, peri- and post-menopausal women: a randomized double-blind, placebo-controlled study. Phytother Res. 2012; 26:510–516.

32. Wiklund IK, Mattsson LA, Lindgren R, Limoni C. Swedish Alternative Medicine Group. Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Int J Clin Pharmacol Res. 1999; 19:89–99.

33. Kim MS, Lim HJ, Yang HJ, Lee MS, Shin BC, Ernst E. Ginseng for managing menopause symptoms: a systematic review of randomized clinical trials. J Ginseng Res. 2013; 37:30–36.

34. Hartley DE, Heinze L, Elsabagh S, File SE. Effects on cognition and mood in postmenopausal women of 1-week treatment with Ginkgo biloba. Pharmacol Biochem Behav. 2003; 75:711–720.

35. Elsabagh S, Hartley DE, File SE. Limited cognitive benefits in Stage +2 postmenopausal women after 6 weeks of treatment with Ginkgo biloba. J Psychopharmacol. 2005; 19:173–181.

36. Heyerick A, Vervarcke S, Depypere H, Bracke M, De Keukeleire D. A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts. Maturitas. 2006; 54:164–175.

37. Erkkola R, Vervarcke S, Vansteelandt S, Rompotti P, De Keukeleire D, Heyerick A. A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts. Phytomedicine. 2010; 17:389–396.

38. MacEoin B. Homeopathy for women. London, UK: Hodder and Stroughton;1996.

39. Bordet MF, Colas A, Marijnen P, Masson J, Trichard M. Treating hot flushes in menopausal women with homeopathic treatment--results of an observational study. Homeopathy. 2008; 97:10–15.

40. Cucherat M, Haugh MC, Gooch M, Boissel JP. Homeopathic Medicines Research Advisory Group. Evidence of clinical efficacy of homeopathy. A meta-analysis of clinical trials. HMRAG. Eur J Clin Pharmacol. 2000; 56:27–33.

41. Ernst E. A systematic review of systematic reviews of homeopathy. Br J Clin Pharmacol. 2002; 54:577–582.

42. Thompson EA, Relton C. Designing clinical trials of homeopathy for menopausal symptoms: a review of the literature. Menopause Int. 2009; 15:31–34.

43. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc. 2002; 77:1207–1218.

44. Berendsen HH. The role of serotonin in hot flushes. Maturitas. 2000; 36:155–164.

45. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003; 289:2827–2834.

46. Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, Bunnell C, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005; 23:6919–6930.

47. Simon JA, Portman DJ, Kaunitz AM, Mekonnen H, Kazempour K, Bhaskar S, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013; 20:1027–1035.

48. Orleans RJ, Li L, Kim MJ, Guo J, Sobhan M, Soule L, et al. FDA approval of paroxetine for menopausal hot flushes. N Engl J Med. 2014; 370:1777–1779.

49. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002; 20:1578–1583.

50. Barton DL, Loprinzi CL, Novotny P, Shanafelt T, Sloan J, Wahner-Roedler D, et al. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol. 2003; 1:47–51.

51. Barton DL, LaVasseur BI, Sloan JA, Stawis AN, Flynn KA, Dyar M, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol. 2010; 28:3278–3283.

52. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998; 16:2377–2381.

53. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000; 356:2059–2063.

54. Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North central cancer treatment group trial N99C7. J Clin Oncol. 2006; 24:1409–1414.

55. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005; 97:30–39.

56. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996; 41:149–156.

57. Guttuso TJ Jr. Gabapentin's effects on hot flashes and hypothermia. Neurology. 2000; 54:2161–2163.

58. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003; 101:337–345.

59. Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005; 366:818–824.

60. Cho SH, Whang WW. Acupuncture for vasomotor menopausal symptoms: a systematic review. Menopause. 2009; 16:1065–1073.

61. Borud EK, Alraek T, White A, Fonnebo V, Eggen AE, Hammar M, et al. The acupuncture on hot flushes among menopausal women (ACUFLASH) study, a randomized controlled trial. Menopause. 2009; 16:484–493.

62. Kim KH, Kang KW, Kim DI, Kim HJ, Yoon HM, Lee JM, et al. Effects of acupuncture on hot flashes in perimenopausal and postmenopausal women--a multicenter randomized clinical trial. Menopause. 2010; 17:269–280.

63. Elraiyah T, Sonbol MB, Wang Z, Khairalseed T, Asi N, Undavalli C, et al. Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014; 99:3536–3542.

64. Ryoo EN, Park KS, Park HM. Study of nurses' knowledge and attitudes on hormone replacement therapy. J Korean Soc Menopause. 2012; 18:43–51.

65. Lee SW, You YO. Bioidentical hormone therapy in postmenopausal women. J Korean Soc Menopause. 2010; 16:6–15.